Loading stock data…
Aura Biosciences, Inc. (AURA)
$6.88-0.12 (-1.71%)
After Hours$6.88+0.00 (+0.00%)· Last close Jun 29
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aura Biosciences, Inc. in the Healthcare sector is trading at $6.88 with a market capitalization of $711M. Wall Street consensus targets $18.80 (5 analysts), implying a +173.3% move over the next 12 months. The stock is currently 28% below its 52-week high of $9.54, remaining 9.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +173.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.87M↓ | -$27.24M↑ | -$27.91M↑ | -$28.61M↑ | -$29.04M |
| Net Income | -$33.69M↓ | -$25.56M↑ | -$26.13M↑ | -$27.02M↑ | -$27.48M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$711.30M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-104.80%
Volume
Today's trading volume
382,988
Recent News
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO Natalie Holles said during a fireside chat at TD Cowen’s se
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial development focus while also discussing ongoing work in non-muscle invasive bladde
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
The consensus price target hints at a 179.8% upside potential for Aura Biosciences (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?